Abbott's XIENCE V(R) Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS(R) Liberte in Investigator-Initiated COM... (information about XIENCE V including imp...)

HOME >> MEDICINE >> TECHNOLOGY

Abbott's XIENCE V(R) Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS(R) Liberte in Investigator-Initiated COMPARE Trial

Date:9/23/2009

information about XIENCE V, including important safety information, is available online at www.xiencev.com or www.abbottvascular.com/en_US/content/document/eIFU_XienceV.pdf.

About Abbott Vascular

Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses. Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development, and advancing medicine through training and education. Headquartered in Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 72,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at www.abbott.com.

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine technology :

1. Abbotts XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial
2. Abbotts XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
3. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
4. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
5. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
6. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
7. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
8. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
9. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
10. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
11. MoxDuo(TM) IR Demonstrates Fewer Side Effects Than Percocet(R)

Post Your Comments:

(Date:11/27/2009)...27/PRNewswire-FirstCall/--Booth-3646/SouthHallA-Va...erofX-raytubesandflatpaneldigitalimagedetectors,wi...tinginChicago,Ill.fromNovember29-December3,2009.Va...iplemodalitiesaswellasspecializedcancertreatmentte...testX-raytechnologyincluding: ,, Abroadarrayof...

(Date:11/25/2009)...,Nov.25/PRNewswire/--PraxisElectronicMedicalRecord...amilyPhysicians,(AAFP)FamilyPracticeManagement(FPM...uality,healthmaintenance,anddiseasemanagement,allc...ked#1amongdoctorsindicatingtheirEMRhadapositiveeff...ednumberoneinthecountryinprovidingexcellenttrainin...

(Date:11/25/2009)...v.25/PRNewswire-FirstCall/--Pharmasset,Inc.(Nasdaq...tedtodiscovering,developingandcommercializingnovel...tsforthefiscalyearendedSeptember30,2009.AtSeptembe...alentsandshortterminvestments. ,, PipelineUpda...bTrial ,, InlateNovember2009,anindependentDat...

Breaking Medicine Technology:Varian Medical Systems to Highlight the Latest Digital Detectors, X-ray Tubes and Cancer Treatment Technology at the Radiological Society of North America (RSNA) Annual Meeting in Chicago 2 Praxis EMR Wins Top Rankings in 2009 AAFP EHR User Satisfaction Survey 2 Pharmasset Reports Fiscal Year End 2009 Financial Results 2 Pharmasset Reports Fiscal Year End 2009 Financial Results 3 Pharmasset Reports Fiscal Year End 2009 Financial Results 4 Pharmasset Reports Fiscal Year End 2009 Financial Results 5 Pharmasset Reports Fiscal Year End 2009 Financial Results 6 Pharmasset Reports Fiscal Year End 2009 Financial Results 7 Pharmasset Reports Fiscal Year End 2009 Financial Results 8 Good Trauma Program Boosts Patient Survival 55023 1 Good Trauma Program Boosts Patient Survival 55023 2 Chemist+Druggist Reveals Frontline NHS Staff Wont Get Swine Flu Vaccine 13647 1 Chemist+Druggist Reveals Frontline NHS Staff Wont Get Swine Flu Vaccine 13647 2 Forty two of Simceres Generic Drugs Enter Chinas Essential Drug List 13646 1 Forty two of Simceres Generic Drugs Enter Chinas Essential Drug List 13646 2

[0] Varian Medical Systems to Highlight the Latest Digital Detectors, X-ray Tubes and Cancer Treatment Technology at the Radiological Society of North America (RSNA) Annual Meeting in Chicago [0] Praxis EMR Wins Top Rankings in 2009 AAFP EHR User Satisfaction Survey [0] Pharmasset Reports Fiscal Year End 2009 Financial Results

...l Molecular Vision -, - Results Show Good Distrib... after a Single Intravitreal Injection -,...oday announced that a study published in the peer-...t bevasiranib, its siRNA (small,interfering RNA) a...extensive uptake into the retina. In two tissue di...

...ystems, Inc.,(Nasdaq: DCTH ) announced today that...rt of St. Luke,s Hospital & Health Network (St. Lu...l for the treatment of,inoperable metastatic melan...Hepatic Perfusion (PHP) System for the isolated, h...an. This Phase III multi-center,study is led by th...

Other Medicine Technology:Newly Published Study Shows OPKO's siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye 2 Newly Published Study Shows OPKO's siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye 3 Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Luke's Cancer Center 2 Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Luke's Cancer Center 3

Newly Published Study Shows OPKO's siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Luke's Cancer Center

(Date:11/27/2009)...,, ROCHESTER,N.Y.,Nov.27/PRNewswire-USNewswi...oviderandfortunatelyeveryyear,newvaccinesarebeinga...ostimmunityforthesameperiodoftime?And,ifnot,whenar...g? ,, Inthismonth,sissueofPediatrics,theJournal...MD,DirectoroftheRochesterGeneralResearchInstitute,...

(Date:11/27/2009)... Soaring rates to bring unprecedented medical, eco..., Nov. 27 (HealthDay News) -- The number of people... double over the next 25 years, a new study predic...ut 44.1 million people with the disease, up from 2...t of treating people with diabetes will triple, th...

(Date:11/27/2009)..., Three new interactive a... Williams & Wilkins expand health sciences lea... Durham, NC (Vocus) November...ams & Wilkins (LWW), a division of Wolters Klu...ree new anatomy education apps on the App Store. C...

(Date:11/26/2009)... Luggage that,s too big or too heavy can lead to s...ealthDay News) -- There may be nothing wrong with ...ht not want to do the same thing with your suitcas...,000 people were treated in 2008 in U.S. hospital ...er medical facilities for luggage-related injuries...

(Date:11/26/2009)..., Benton Communications a...iness growth system for retailers struggling to ma... (PRWEB) November 26, 2009 -- Flu fears is the ty...es to the emergency room, according to Dr. David B...wly released business growth system – The R...

Breaking Medicine News(10 mins):Health News:Why Some Vaccines May Require A Booster 2 Health News:Why Some Vaccines May Require A Booster 3 Health News:Diabetes Cases Expected to Double in 25 Years 2 Health News:Diabetes Cases Expected to Double in 25 Years 3 Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 2 Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 3 Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 4 Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 5 Health News:Pack Right for the Holidays to Avoid the ER 2 Health News:Pharmacist Injects Cure for Ailing Businesses 2

[0] Why Some Vaccines May Require A Booster [0] Diabetes Cases Expected to Double in 25 Years [0] Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store [2] Pack Right for the Holidays to Avoid the ER [1] Pharmacist Injects Cure for Ailing Businesses

... fewer calories, lower sodium, and comparable ...- -Study also cites lower production costs a...C Bulletin,Board: NTRZ), a world leader in stabili...ngredient Technologies, an,independent research fi...

...sion Inc. (Nasdaq:,LCAV), a leading provider of la...(R) brand, announced the opening of its 76th Lasik...his opening marks the fourth,LasikPlus(R) vision c...l 2006., Similar to other LasikPlus(R) vision cen...

...rdiac Science,Corporation (Nasdaq: CSCX ), a glob...ion, rehabilitation, and informatics products, ann...ology conference that it completed,certification f...ased practice management and electronic medical re...

...line Health,Solutions, Inc. (Nasdaq: STRM ) today...arter and fiscal year ended January 31, 2008., Re...ere $5.6 million, a,47% increase, compared with $3... Operating Profit of $309 thousand in the,fourth q...

...31 Ingenuity Systems, the,leading provider of inf...nounced today that Path Designer, the new pathway ... New Product by the scientific community in,attend...o more clearly communicate their experimental find...

...ating the uninsured through automated eligibility...stance programs, C...its,healthcare financing method was granted United...es, in real time, patient,eligibility for financia...

NutraCea-Sponsored Study Demonstrates Benefits of Replacing Wheat Flour with Stabilized Rice Bran (SRB) in Battered and Fried Product Applications LCA-Vision Announces the Opening of its 76th LasikPlus(R) Vision Center in Woodbridge, New Jersey Cardiac Science Adds NextGen to Its Roster of Certified EMR System Partners Streamline Health Solutions, Inc. Reports Fourth Quarter and Fiscal Year 2007 Results Ingenuity's Path Designer is Selected as Best New Product by Life Science Community at 2008 Molecular Medicine Conference The United States Patent and Trademark Office Grants TransUnion Patent for Healthcare Financing Method

BacT/Alert 3D Signature

Vitek 2

IDS Rapid ANA II System

IDS Rapid SS/u

Medicine Products:

BacT/Alert 3D Signature Vitek 2 IDS Rapid ANA II System IDS Rapid SS/u

Abbott's XIENCE V(R) Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS(R) Liberte in Investigator-Initiated COM...(information about XIENCE V including imp...),Health